Panasonic Healthcare Holdings agreed Wednesday to acquire the diabetes devices business of German conglomerate Bayer for 1.02 billion euros.
Bayer Diabetes Care or BDC, is one of the leading providers of blood glucose monitoring systems to people with diabetes and healthcare professionals around the world.
The company expects to close the deal in the first quarter of 2016, subject to customary closing conditions, including relevant antitrust clearance.
“We are confident that the sale of our Diabetes Care business to our long-standing partner Panasonic Healthcare, with the strong backing of KKR, will support the long-term sustainability of this portfolio,” said Werner Baumann, member of the Board of Management of Bayer AG and CEO of Bayer HealthCare.
Full content: Blouin News
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Dismisses Antitrust Lawsuit Against Ivy League Over Athletic Scholarships
Oct 11, 2024 by
CPI
FTC and DOJ Revamp Merger Guidelines to Identify Illegal Transactions More Efficiently
Oct 11, 2024 by
CPI
US Consumer Watchdog Eyes Expansion of ‘Junk Fee’ Crackdown Ahead of 2024 Election
Oct 10, 2024 by
CPI
Brazil Proposes Reform to Competition Law Targeting Big Tech
Oct 10, 2024 by
CPI
Meta Enhances User Data Control, Resolving German Antitrust Dispute
Oct 10, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Refusal to Deal
Sep 27, 2024 by
CPI
Antitrust’s Refusal-to-Deal Doctrine: The Emperor Has No Clothes
Sep 27, 2024 by
Erik Hovenkamp
Why All Antitrust Claims are Refusal to Deal Claims and What that Means for Policy
Sep 27, 2024 by
Ramsi Woodcock
The Aspen Misadventure
Sep 27, 2024 by
Roger Blair & Holly P. Stidham
Refusal to Deal in Antitrust Law: Evolving Jurisprudence and Business Justifications in the Align Technology Case
Sep 27, 2024 by
Timothy Hsieh